Month: February 2025

AUSTIN, Texas, Feb. 10, 2025 (GLOBE NEWSWIRE) — After one year of John Kim at the helm of Volcon ePowersports, their recent successes can be attributed to his strategic shift. In the last 12 months Mr. Kim was able to switch Volcon from being a mostly R&D organization developing its own electric offroad technologies into a company that is focused on collaborating with manufacturers to brand and sell high-quality electric vehicles. This has positioned Volcon to be a true disruptor in the ePowersports business, which was made especially apparent with their recent AODES (Super Sonic) collaboration. Volcon’s AODES (Super Sonic) announcement allowed them to raise $19.45 million to fund their foray into the golf cart and utility vehicle market. Bringing high-quality, low-cost electric vehicles from Vietnam into the US market creates...

MIAMI, Feb. 10, 2025 (GLOBE NEWSWIRE) — Varonis Systems, Inc. (Nasdaq: VRNS), a leader in data security, announced that its board of directors authorized a share repurchase program allowing repurchases of up to $100.0 million of Varonis’ common stock expected to be completed over the next 12 months. Under the share repurchase program, Varonis is authorized to repurchase shares through open market purchases, privately-negotiated transactions or otherwise in accordance with applicable federal securities laws, including through Rule 10b5-1 trading plans and under Rule 10b-18 of the Exchange Act. The number of shares to be purchased and the timing of purchases will be based on Varonis’ trading windows, available liquidity, and general business and market conditions. Forward-Looking Statements This press release contains “forward-looking”...

No Safety Concerns Identified by DSMC in the ORCA-OL Long-Term Exposure Trial Achieve Reiterates Planned Cytisinicline NDA Submission in Q2 2025 SEATTLE and VANCOUVER, British Columbia, Feb. 10, 2025 (GLOBE NEWSWIRE) — Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced that the Data Safety Monitoring Committee (DSMC) has recently completed its second independent review of the ongoing ORCA-OL trial, evaluating long-term exposure of the novel 3 mg cytisinicline treatment dosing regimen in individuals who smoke cigarettes or vape nicotine. Following this second comprehensive review of available safety data, the DSMC stated that it did not identify any unexpected...

This Marks the Third Location Opening in 2025 Signaling Strong Growth Momentum for the Year CERRITOS, Calif., Feb. 10, 2025 (GLOBE NEWSWIRE) — GEN Restaurant Group, Inc. (“GEN” or the “Company”) (Nasdaq: GENK), owner of GEN Korean BBQ, a fast-growing casual dining concept with an extensive menu and signature “grill at your table” experience, today announced a new restaurant location in San Antonio, Texas, which opened on January 31, 2025. This marks the Company’s third new opening in January, following successful additions in Edison, New Jersey and Orlando, Florida. “Opening a sixth Texas location in a new market was a natural choice for GEN given the strong performance of our existing Texas locations and desire to continue building momentum across the state,” said David Kim, Chairman and CEO of GEN. “We are proud to have started...

COOTAMUNDRA, Australia, Feb. 10, 2025 (GLOBE NEWSWIRE) — Australian Oilseeds Holdings Limited, a Cayman Islands exempted company (the “Company”) (NASDAQ: COOT) today announced financial results for its first quarter fiscal 2025 ended September 30, 2024. First Quarter Fiscal 2025 Financial Highlights Compared to Prior YearSales revenue increased 6.1% to A$10.4 million due to strong demand for the Company’s cold pressed canola oil.Retail oil revenue increased 59.9% to A$5.7 million due to expanded distribution in leading retailers in Australia along with the addition of several new SKUs.Net loss of A$0.6 million compared to net income of A$1.4 million, reflecting changes to sales mix along with the timing of planned investments in brand and marketing to support our GEO products.Cash flow from operations improved to A$0.6...

REDWOOD CITY, Calif., Feb. 10, 2025 (GLOBE NEWSWIRE) — Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today announced five poster presentations and an oral presentation of briquilimab data at the AAAAI 2025 Annual Meeting, being held February 28 – March 3, 2025, in San Diego, CA. The oral presentation and one of the poster presentations will include additional follow-up from patients included in the Company’s January 8th, 2025, disclosure of preliminary data from the Phase 1b/2a BEACON trial evaluating briquilimab in CSU. Details of the presentations are as follows: Abstract...

Total new customer application volume in January 2025 increased 130% year-over-year, driving the highest level of January originations, with total originations up 44% year-over-year Monthly growth trends accelerated in January 2025, compared to December 2024 Indicators of profitability for January 2025 are encouraging with 105% increase in FlexShopper.com gross margin dollars, a 34% year-over-year reduction in marketplace marketing cost per new customer, and stable asset quality BOCA RATON, Fla., Feb. 10, 2025 (GLOBE NEWSWIRE) — FlexShopper, Inc. (Nasdaq: FPAY), a prominent national online lease-to-own retailer and payment solutions provider, today announced another strong operating month for January 2025. Positive momentum reflects the successful transformation underway as a result of FlexShopper’s direct-to-consumer (DTC) and...

WORCESTER, Mass., Feb. 10, 2025 (GLOBE NEWSWIRE) — Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell therapies into potential cures for difficult-to-treat cancers, today announced the closing of its previously announced public offering, for the issuance and sale of an aggregate of 2,657,807 shares of its common stock (or common stock equivalents in lieu thereof), Series C-1 warrants to purchase up to 2,657,807 shares of common stock and Series C-2 warrants to purchase up to 2,657,807 shares of common stock, at a combined public offering price of $3.01 per share (or per common stock equivalent in lieu thereof) and accompanying warrants. The warrants have an exercise price of $3.01 per share and will be exercisable...